Currently Viewing:
Newsroom
Currently Reading
Insomnia Correlated to an Increased Risk of Heart Disease and Stroke, Study Shows
August 19, 2019 – Matthew Gavidia
Inspiratory Muscle Training May Be an Option for Patients Who Decline Pulmonary Rehabilitation for COPD
August 18, 2019 – Kelly Davio
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez

Study Identifies IVM as Potential Candidate to Promote Remyelination for MS

Alison Rodriguez
A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation, finding that P2X4 receptors modulate microglia/macrophage inflammatory responses and identify allosteric modulator ivermectin (IVM) as a potential candidate to promote the repair of myelin damage.
Multiple sclerosis (MS) is a chronic inflammatory disease of the brain and spinal cord that attacks and destroys the myelin sheath, leading to demyelination and neurodegeneration. A recent study analyzed the role of purinergic receptor P2X4 (P2X4R) in microglia/macrophages during autoimmune inflammation, finding that P2X4Rs modulate microglia/macrophage inflammatory responses and identify allosteric modulator ivermectin (IVM) as a potential candidate to promote the repair of myelin damage.

The study, published by EMBO Molecular Medicine, explained how microglia survey the brain microenvironment for signals of injury or infection; understanding these mechanisms of microglia responses during pathology are important for promoting regenerative responses. The researchers were able to identify the receptor P2X4 present in the microglial cells that increases the antiinflammatory potential and encourages the body’s own repair responses.

“Innate immune cells contribute to axonal damage and demyelination in MS but they are also pivotal in promoting repair responses. Modulating microglia/macrophage P2X4R activation determines clinical outcome in the experimental autoimmune encephalomyelitis (EAE) model of MS,” the study stated.

The experiment was conducted using animal models of the disease, which revealed that the drugs that activate the P2X4R receptor also improve the symptoms during the chronic phase of the disease when continuing the repair of nervous tissue.

The main findings of the study, involving P2X4R included:
  • Expression of P2x4r and the 2 transcription factors controlling its expression, Irf8 and Irf5, was increased in the EAE.
  • EAE clinical symptoms were exacerbated by the P2X4R blockage and ameliorated by P2X4R potentiation with the IVM.
  • P2X4R blockage does not interfere with the immune priming or with blood‐brain‐barrier permeability during the acute phase of EAE.
  • P2X4R activation favors a switch of microglia/macrophage to an anti‐inflammatory phenotype and increases BDNF release, that promotes oligodendrocyte differentiation.
  • P2X4R activation increases myelin phagocytosis and degradation at lysosomes, thus indirectly promoting remyelinating responses.
Specifically, the researchers emphasized that the P2X4R signaling by the IVM favored a switch in microglia to an antiinflammatory phenotype, potentiated myelin phagocytosis, promoted the remyelination response, and ameliorated clinical signs of EAE. 

“Mechanistically, P2X4 receptor signaling potentiation in microglia/macrophages favors a switch to an anti‐inflammatory phenotype that, by secreting factors such as BDNF and increasing myelin phagocytosis, leads to higher remyelination,” explained the researchers. “Altogether, data here suggest that P2X4R upregulation could be a marker of the neuroinflammatory response in MS and that potentiation of signaling by P2X4R has therapeutic potential to treat demyelinating disorders.”

 


Related Articles

Epigenetic Regulation of HLA Region Increases Risk of Multiple Sclerosis
Studies Evaluate Effects of Secondary Progressive Multiple Sclerosis
Patients With Multiple Sclerosis Need Better Dietary Education From Providers
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up